Bone Biologics Corp — Director's Dealing 2026

Jan 21, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2026-01-08

Reporting Person: Frelick Jeff (Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-08	Employee Stock Option	$1.55	A	16668	Acquired	2036-01-08	Common Stock (16668)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	360	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option	$5.82	2027-01-15	Common Stock (9019)	9019	Direct
Employee Stock Option	$73800	2026-05-26	Common Stock (8)	8	Direct

Footnotes

F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

F2: This option is fully vested as of the date of this report.